The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Advances and unanswered questions in AML: novel agents, MRD assessment, and immunotherapy
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses recent developments in acute myeloid leukemia (AML) treatment, highlighting the importance of venetoclax, particularly in older patients, and the ongoing questions about optimal dosing. He also emphasizes the potential of FLT3 inhibitors, measurable residual disease (MRD) assessment, and emerging agents like menin inhibitors for AML subtypes such as KMT2A and NPM1. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
